Feds open criminal probe into opioid makers

Pharmaceutical companies are under fire again for their role in the national opioid abuse epidemic and, this time, it could be criminal. Federal prosecutors have opened a criminal probe to determine if pharmaceutical companies intentionally allowed the flow of opioid drugs, The Wall Street Journal reported.

The investigation could be the largest prosecution of drug companies related to their actions and impact on the opioid epidemic if criminal charges are brought. Six companies, including Teva Pharmaceuticals, Mallinckrodt, Johnson & Johnson, Amneal Pharmaceuticals, AmerisourceBergen and McKesson, are facing grand jury subpoenas from the U.S. attorney’s office in the Eastern District of New York, according to the WSJ.

Drug companies are already facing thousands of lawsuits from individual states for their role in opioid harms, with Purdue Pharma filing for bankruptcy as part of a $10 billion settlement deal to resolve all pending litigation against the company, which is the maker of the powerful opioid OxyContin.

The companies facing the federal criminal investigation have denied wrongdoing, stating they’ve followed “all laws around the manufacture and distribution of opioid prescription painkillers,” the WSJ reported.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.